Briacell Therapeutics Corp (BCTX) Stock Price, Quote & News

Company Profile

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agree...

Industry: Biotechnology

Sector: Healthcare

Phone: 604 921 1810

Fax: 604 921 1898

Website: briacell.com

Address:

Bellevue Centre, Suite 300 235 -15th Street, West Vancouver, Canada

MollyWantsACracker Jan. 22 at 6:54 PM

$KOLD , $ELBM, $BCTX, $UVIX -- nice to be up and green in everything I'm holding, and yes, even a little green in UVIX.

0 · Reply

Forestbird Jan. 22 at 6:45 PM

$BCTX should return to 7-8 level in short term.

0 · Reply

JediGreen Jan. 22 at 6:41 PM

$BCTX

0 · Reply

kikon81 Jan. 22 at 6:41 PM

$BCTX maybe AH?

0 · Reply

Kirubin Jan. 22 at 6:15 PM

$BCTX 🥶🥶! Go back to 250K share! Delusional!

0 · Reply

DanishViking92 Jan. 22 at 6:14 PM

$BCTX Rated #1 this week! https://www.biostockinfo.com/biotech-catalyst-ai-scanner-january-wk3/

0 · Reply

DanishViking92 Jan. 22 at 5:26 PM

$BCTX

0 · Reply

DanishViking92 Jan. 22 at 5:22 PM

$BCTX

0 · Reply

MollyWantsACracker Jan. 22 at 3:18 PM

$BCTX might be the beginning of a reversal

3 · Reply

MollyWantsACracker Jan. 22 at 1:36 PM

$BCTX For what it is worth... BENZINGA Jan-19-2026 11:00 a.m. ET BriaCell Therapeutics Corp's (BCTX) short interest as a percent of float has risen 174.82% since its last report. According to exchange reported data, there are now 281 thousand shares sold short, which is 14.95% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.79 days to cover their short positions on average.

1 · Reply

BriaCell Therapeutics Announces Closing of US$30 million Public Offering

Jan 13, 2026, 9:00 PM EST - 8 days ago

BriaCell Therapeutics Announces Pricing of $30 million Public Offering

Jan 13, 2026, 7:30 AM EST - 9 days ago

BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Patient

Dec 18, 2025, 7:30 AM EST - 5 weeks ago

“Eleven clinical trials that will shape medicine in 2026” – BriaCell Phase 3 Trial Featured in Nature Medicine

Dec 10, 2025, 7:30 AM EST - 6 weeks ago

BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025

Dec 9, 2025, 7:30 AM EST - 6 weeks ago

BriaCell's Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout

Dec 2, 2025, 7:30 AM EST - 7 weeks ago

BriaCell to Present Phase 2 Survival & Phase 3 Clinical Data at SABCS® 2025

Nov 25, 2025, 7:30 AM EST - 2 months ago

BriaCell to Highlight Positive Phase 2 & Phase 3 Clinical Data at SABCS® 2025

Nov 20, 2025, 7:30 AM EST - 2 months ago

BriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics

Nov 18, 2025, 7:30 AM EST - 2 months ago

BriaCell Selected to Present Phase 2 & 3 Clinical Data at SABCS® 2025

Nov 7, 2025, 7:30 AM EST - 2 months ago

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ at SITC 2025

Nov 4, 2025, 7:30 AM EST - 2 months ago

BriaCell to Present Robust Anti-Cancer Activity of Bria-OTS+™ in Breast and Prostate Cancer Models

Oct 22, 2025, 7:30 AM EDT - 3 months ago

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

Oct 21, 2025, 7:50 AM EDT - 3 months ago

BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study

Oct 21, 2025, 7:30 AM EDT - 3 months ago

BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+™ for Breast Cancer

Oct 20, 2025, 7:30 AM EDT - 3 months ago

BriaCell Presents Phase 3 Clinical Biomarker Data at ESMO 2025

Oct 13, 2025, 7:30 AM EDT - 3 months ago

BriaCell to Present Positive Clinical Biomarker Data of Phase 3 Study at ESMO 2025

Oct 3, 2025, 7:30 AM EDT - 3 months ago

BriaCell to Present Bria-OTS+™ Preclinical Data at SITC 2025 Annual Meeting

Aug 26, 2025, 7:30 AM EDT - 5 months ago

BriaCell's Bria-OTS+™ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal

Aug 25, 2025, 7:30 AM EDT - 5 months ago

BriaCell Awarded $2 Million NCI Grant to Advance Bria-PROS+™ in Prostate Cancer

Aug 21, 2025, 12:00 PM EDT - 5 months ago

BriaCell Announces Proposed Effective Date of Share Consolidation

Aug 13, 2025, 7:30 AM EDT - 5 months ago

BriaCell Selected for MSK's 2025 Therapeutics Accelerator Program for Bria-OTS+™ for Cancer

Jul 31, 2025, 7:30 AM EDT - 6 months ago

BriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer Study

Jul 30, 2025, 7:30 AM EDT - 6 months ago

BriaCell Awarded New Zealand Patent for its Whole Cell Technology

Jul 29, 2025, 7:30 AM EDT - 6 months ago

BriaCell's Subsidiary, BriaPro, Files Patent Application for Immuno-Oncology Platform with Novel Multitargeting Agents

Jul 25, 2025, 7:30 AM EDT - 6 months ago

BriaCell Announces Two Clinical Data Poster Presentations at ESMO 2025

Jul 16, 2025, 4:05 PM EDT - 6 months ago

BriaCell Therapeutics Announces Closing of $15 million Public Offering

Jul 15, 2025, 3:05 PM EDT - 6 months ago

BriaCell Therapeutics Announces Pricing of $15 million Public Offering

Jul 15, 2025, 7:30 AM EDT - 6 months ago

BriaCell Adds Mayo Clinic to Phase 3 Study in Metastatic Breast Cancer

Jul 11, 2025, 7:30 AM EDT - 6 months ago

BriaCell's Bria-IMT™ Demonstrates Survival Advantage over Trodelvy® and Control Group in Metastatic Breast Cancer

Jul 10, 2025, 7:30 AM EDT - 7 months ago

BriaCell Reports Complete and Sustained Resolution of Brain Metastasis and Sustained Regression of Orbital Metastasis in “Eye-Bulging” Breast Cancer Patient

Jul 9, 2025, 7:30 AM EDT - 7 months ago

BriaCell Patient Achieves Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Metastatic Breast Cancer Study

Jul 8, 2025, 7:30 AM EDT - 7 months ago

BriaCell Phase 2 Survival Achievement: 52% of Patients Surpass One-Year Milestone in Metastatic Breast Cancer

Jul 2, 2025, 7:30 AM EDT - 7 months ago

BriaCell Highlights Additional Phase 3 Clinical Sites Including Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven

Jun 24, 2025, 7:30 AM EDT - 7 months ago

BriaCell Announces Positive Recommendation from Data Safety Monitoring Board for Pivotal Phase 3 Study in Metastatic Breast Cancer

Jun 4, 2025, 7:30 AM EDT - 8 months ago

BriaCell Announces Virtual Investor Presentations on Thursday, June 12 and Thursday, June 26

Jun 2, 2025, 7:30 AM EDT - 8 months ago

BriaCell Reports Robust Overall Survival and Clinical Benefit Data at ASCO 2025

May 27, 2025, 7:30 AM EDT - 8 months ago

BriaCell Bria-OTS™ Phase 1/2 Study Clears Safety Evaluation; Doses First Patient in Combination with Checkpoint Inhibitor

May 23, 2025, 7:30 AM EDT - 8 months ago

BriaCell Abstracts Showcase Positive Survival and Clinical Benefit Data at ASCO 2025

May 20, 2025, 7:30 AM EDT - 8 months ago

BriaCell CEO Letter to Shareholders

Apr 30, 2025, 7:30 AM EDT - 9 months ago

BriaCell Reports “Late-Breaker” Phase 3 Data at AACR 2025: Positive Tolerability Profile and Potential Response Biomarkers Identified

Apr 28, 2025, 4:05 PM EDT - 9 months ago

BriaCell Therapeutics Announces Closing of $13.8 million Public Offering

Apr 28, 2025, 7:30 AM EDT - 9 months ago

BriaCell Presents Benchmark Beating Survival and Clinical Benefit at AACR 2025; Advancements in Next Generation Bria-OTS+™ Development

Apr 24, 2025, 8:00 PM EDT - 9 months ago

BriaCell Therapeutics Announces Pricing of $13.8 million Public Offering

Apr 24, 2025, 10:11 AM EDT - 9 months ago

Nano-Cap BriaCell Confirms Full Resolution Of Lung Metastasis In Breast Cancer Trial, Stock Shoots Higher

Apr 24, 2025, 7:30 AM EDT - 9 months ago

BriaCell Confirms 100% Resolution of Lung Metastasis with Bria-OTS™

Apr 23, 2025, 7:30 AM EDT - 9 months ago

BriaCell Announces Four Clinical Data Presentations at ASCO 2025

Apr 22, 2025, 7:30 AM EDT - 9 months ago

BriaCell Enrollment Pace Accelerating in Phase 3 Clinical Study in Advanced Metastatic Breast Cancer (Bria-ABC)

Apr 16, 2025, 7:30 AM EDT - 10 months ago

BriaCell Phase 2 Survival Data Beats Leading Standard in HR+ Breast Cancer

Mar 26, 2025, 8:00 AM EDT - 10 months ago

BriaCell to Present Clinical and Preclinical Data at the 2025 AACR Conference

MollyWantsACracker Jan. 22 at 6:54 PM

$KOLD , $ELBM, $BCTX, $UVIX -- nice to be up and green in everything I'm holding, and yes, even a little green in UVIX.

0 · Reply

Forestbird Jan. 22 at 6:45 PM

$BCTX should return to 7-8 level in short term.

0 · Reply

JediGreen Jan. 22 at 6:41 PM

$BCTX

0 · Reply

kikon81 Jan. 22 at 6:41 PM

$BCTX maybe AH?

0 · Reply

Kirubin Jan. 22 at 6:15 PM

$BCTX 🥶🥶! Go back to 250K share! Delusional!

0 · Reply

DanishViking92 Jan. 22 at 6:14 PM

$BCTX Rated #1 this week! https://www.biostockinfo.com/biotech-catalyst-ai-scanner-january-wk3/

0 · Reply

DanishViking92 Jan. 22 at 5:26 PM

$BCTX

0 · Reply

DanishViking92 Jan. 22 at 5:22 PM

$BCTX

0 · Reply

MollyWantsACracker Jan. 22 at 3:18 PM

$BCTX might be the beginning of a reversal

3 · Reply

MollyWantsACracker Jan. 22 at 1:36 PM

1 · Reply

MollyWantsACracker Jan. 22 at 1:23 PM

$BCTX I ended up selling half yesterday and buying back this am. My ave is $4.36 currently.

1 · Reply

DanishViking92 Jan. 22 at 5:00 AM

$BCTX look at that AH spike! That tells me something is cooking and that its going to be an exciting day to come! $$ GL bulls

1 · Reply

JediGreen Jan. 21 at 10:17 PM

$BCTX phase 3 read out not to far away.

1 · Reply

DanishViking92 Jan. 21 at 9:53 PM

$BCTX i have seen this story over and over again - it will gap up.. its happening all the time with such stock drops due to offering with major upcoming catalyst. It drops, people get scared and sell, then it pumps up and then it drops again. I am here for the big pump! $$

0 · Reply

Rohtan Jan. 21 at 7:19 PM

$BCTX below 4 soon

1 · Reply

MollyWantsACracker Jan. 21 at 7:01 PM

$BCTX Disapointed and a bit surprised with the price action today

1 · Reply

DanishViking92 Jan. 21 at 6:49 PM

$BCTX

1 · Reply

DanishViking92 Jan. 21 at 5:17 PM

$BCTX

0 · Reply

DanishViking92 Jan. 21 at 4:59 PM

$BCTX is trading below cash level =

0 · Reply

DanishViking92 Jan. 21 at 4:29 PM

$BCTX just a little dip day before we rip to $20S and burn the shorting morons!

0 · Reply

DanishViking92 Jan. 21 at 3:43 PM

Buy $BCTX and support a very important treatment - breast cancer is widely spread and causes thousands of deaths every year!

1 · Reply

roomza Jan. 21 at 2:44 PM

$BCTX bottom forming??

1 · Reply

Market Cap	8.23M
Revenue (ttm)	0.00
Net Income (ttm)	-26.31M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	224,581
Avg Vol	374,616
Day's Range	N/A - N/A
Shares Out	1.88M
Stochastic %K	1%
Beta	1.38
Analysts	Strong Buy
Price Target	$40.00